| 9001 | HAVCR2 levels | GCST90421515 | 1.37e-03 |
| 9002 | SLA2 levels | GCST90470648 | 1.37e-03 |
| 9003 | Other and/or unspecified nontoxic goitre | FING00000958 | 1.37e-03 |
| 9004 | BACH1/EIF4G1 ratio | GCST90313438 | 1.37e-03 |
| 9005 | PRKRA levels | GCST90470331 | 1.36e-03 |
| 9006 | Congenital malformations of the circulatory system | FING00000340 | 1.36e-03 |
| 9007 | Disorders of lipoprotein metabolism and other lipidaemias | FING00000442 | 1.36e-03 |
| 9008 | Phlebitis and thrombophlebitis (not including DVT) | FING00001165 | 1.36e-03 |
| 9009 | ANGPT1/EGF ratio | GCST90313264 | 1.35e-03 |
| 9010 | Bleeding | FING00000219 | 1.35e-03 |
| 9011 | Sphingomyelin_39:1_[M+H]1+ levels | GCST90060328 | 1.35e-03 |
| 9012 | Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T89 | ECGA000089 | 1.35e-03 |
| 9013 | HLAE/IL15 ratio | GCST90315061 | 1.35e-03 |
| 9014 | aparc-a2009s lh area S-orbital-med-olfact | GCST90003359 | 1.35e-03 |
| 9015 | Cholesterol to total lipids in large VLDL percentage (UKB data field 23590) | GCST90269687 | 1.34e-03 |
| 9016 | DTI TBSS MD Posterior corona radiata R | GCST90384598 | 1.34e-03 |
| 9017 | 1-stearoyl-2-docosahexaenoyl-GPE (18:0/22:6) levels | GCST90200065 | 1.34e-03 |
| 9018 | PDGFB/SPINT2 ratio | GCST90315629 | 1.34e-03 |
| 9019 | CASP1 levels | GCST90468543 | 1.34e-03 |
| 9020 | IDP dMRI TBSS ISOVF Posterior corona radiata L | GCST90004504 | 1.34e-03 |
| 9021 | CELA3A/PLA2G1B ratio | GCST90314014 | 1.34e-03 |
| 9022 | Free Cholesterol to Total Lipids in Small HDL percentage | GCST90499431 | 1.33e-03 |
| 9023 | HPSE levels | GCST90469473 | 1.33e-03 |
| 9024 | Disorders of sclera, cornea, iris and ciliary body | FING00000458 | 1.33e-03 |
| 9025 | Illnesses of father - None of the above (group 2) | Family history | UKBB00000346 | 1.33e-03 |
| 9026 | SCARA3 levels | GCST90427856 | 1.33e-03 |
| 9027 | MANF/PDGFB ratio | GCST90315360 | 1.33e-03 |
| 9028 | C21orf58 levels | GCST90618380 | 1.33e-03 |
| 9029 | Phosphatidylcholine-O_33:3_[M+H]1+/Phosphatidylcholine-P_33:2_[M+H]1+/Phosphatidylethanolamine-O_36:3_[M+H]1+ levels | GCST90060261 | 1.33e-03 |
| 9030 | ITGB1/REG1A ratio | GCST90315228 | 1.33e-03 |
| 9031 | Cardiovascular delta age (difference between ECG-predicted and chronological age) | GCST90239749 | 1.32e-03 |
| 9032 | aparc-Desikan lh area pericalcarine | GCST90003093 | 1.32e-03 |
| 9033 | IL19 levels | GCST90469568 | 1.32e-03 |
| 9034 | Triglycerides to total lipids in large VLDL percentage (UKB data field 23593) | GCST90269690 | 1.31e-03 |
| 9035 | ICD10 O14: Pre-eclampsia | GCST90454233 | 1.31e-03 |
| 9036 | Saturated fatty acids levels | GCST90502671 | 1.31e-03 |
| 9037 | MYOM3 levels | GCST90469986 | 1.31e-03 |
| 9038 | Uric acid levels | GCST90278646 | 1.30e-03 |
| 9039 | hemoglobin (mean, inv-norm transformed) | GCST90475376 | 1.30e-03 |
| 9040 | CRACR2A/LBR ratio | GCST90314228 | 1.30e-03 |
| 9041 | Omega-6 fatty acid levels | GCST90502503 | 1.30e-03 |
| 9042 | Free cholesterol in very large HDL | GCST90500383 | 1.30e-03 |
| 9043 | CRKL/MGLL ratio | GCST90314270 | 1.30e-03 |
| 9044 | Systolic blood pressure, manual reading | Blood pressure | UKBB00000810 | 1.30e-03 |
| 9045 | Total phospholipid levels in lipoprotein particles | GCST90500124 | 1.30e-03 |
| 9046 | C1QL2 levels | GCST90468487 | 1.30e-03 |
| 9047 | Calculus of lower urinary tract (PheCode 594.2) | GCST90476146 | 1.29e-03 |
| 9048 | MINDY1 levels | GCST90469908 | 1.29e-03 |
| 9049 | Cholesteryl Esters to Total Lipids in Large VLDL percentage | GCST90498165 | 1.29e-03 |
| 9050 | Triglycerides to Total Lipids in Large VLDL percentage | GCST90498293 | 1.29e-03 |
| 9051 | CST3/CTSZ ratio | GCST90314290 | 1.29e-03 |
| 9052 | TNFAIP2 levels | GCST90470896 | 1.29e-03 |
| 9053 | Psoriatic arthritis | GCST90243956 | 1.29e-03 |
| 9054 | CXCL10 levels | GCST90468923 | 1.29e-03 |
| 9055 | Right-hemisphere visual network to right-hemisphere default mode network white-matter structural connectivity | GCST90302780 | 1.28e-03 |
| 9056 | CALB1 levels | GCST90468526 | 1.28e-03 |
| 9057 | GRAP2/LACTB2 ratio | GCST90314980 | 1.28e-03 |
| 9058 | Triglycerides in LDL | GCST90498469 | 1.28e-03 |
| 9059 | Psoriasis and related disorder (PheCode 696) | GCST90476186 | 1.28e-03 |
| 9060 | AmygNuclei rh volume Lateral-nucleus | GCST90002658 | 1.28e-03 |
| 9061 | FCAR/LY96 ratio | GCST90314788 | 1.28e-03 |
| 9062 | T1 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 41) | GCST90320604 | 1.27e-03 |
| 9063 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T468 | ECGU000468 | 1.27e-03 |
| 9064 | Prescriptions - biguanides|diabetes | UKBB00000671 | 1.27e-03 |
| 9065 | Phospholipids to total lipids in chylomicrons and extremely large VLDL percentage (UKB data field 23579) | GCST90269676 | 1.27e-03 |
| 9066 | Acute appendicitis | FING00000017 | 1.27e-03 |
| 9067 | Phospholipids to total lipids in medium LDL percentage (UKB data field 23619) | GCST90269716 | 1.27e-03 |
| 9068 | HEPH levels | GCST90469446 | 1.27e-03 |
| 9069 | Phospholipids in HDL (UKB data field 23414) | GCST90269511 | 1.27e-03 |
| 9070 | Tibiofemoral angle | GCST90270263 | 1.26e-03 |
| 9071 | RABGAP1L levels | GCST90470416 | 1.26e-03 |
| 9072 | Ulcerative colitis | GCST90468152 | 1.26e-03 |
| 9073 | JAM2/RGMB ratio | GCST90315237 | 1.26e-03 |
| 9074 | HYOU1/PTPRF ratio | GCST90315102 | 1.26e-03 |
| 9075 | IDP T1 FAST ROIs R cerebellum crus I | GCST90002571 | 1.26e-03 |
| 9076 | Creatinine levels | GCST90092815 | 1.26e-03 |
| 9077 | CLIP2/NT5C3A ratio | GCST90314129 | 1.26e-03 |
| 9078 | aparc-pial lh area precentral | GCST90003164 | 1.26e-03 |
| 9079 | Phosphatidylcholine levels | GCST90499248 | 1.26e-03 |
| 9080 | Cholesterol to total lipids ratio in very large HDL | GCST90093005 | 1.26e-03 |
| 9081 | CASP3 levels | GCST90468545 | 1.26e-03 |
| 9082 | Pulmonary embolism and infarction, acute (PheCode 415.11) | GCST90475946 | 1.25e-03 |
| 9083 | triglyceride (minimum, inv-norm transformed) | GCST90476437 | 1.25e-03 |
| 9084 | MGLL/PDLIM7 ratio | GCST90315438 | 1.25e-03 |
| 9085 | Barrett's esophagus (PheCode 530.13) | GCST90476048 | 1.25e-03 |
| 9086 | NMNAT1 levels | GCST90470057 | 1.25e-03 |
| 9087 | Total lipid levels in lipoprotein particles | GCST90500085 | 1.25e-03 |
| 9088 | IGFBP6/PTGDS ratio | GCST90315137 | 1.25e-03 |
| 9089 | AGRN/CRIM1 ratio | GCST90313200 | 1.25e-03 |
| 9090 | S100A16 levels | GCST90470516 | 1.24e-03 |
| 9091 | Asthma | GCST010042 | 1.24e-03 |
| 9092 | CD63/CLEC1B ratio | GCST90313863 | 1.24e-03 |
| 9093 | CRELD2 levels | GCST90468859 | 1.24e-03 |
| 9094 | ADGRG2/ITGB1 ratio | GCST90313185 | 1.23e-03 |
| 9095 | Average diameter for HDL particles | GCST90497446 | 1.23e-03 |
| 9096 | Platelet count during third trimester of pregnancy | GCST90302226 | 1.23e-03 |
| 9097 | BCR/DECR1 ratio | GCST90313489 | 1.23e-03 |
| 9098 | Prescriptions - metformin | biguanides,diabetes | UKBB00000692 | 1.23e-03 |
| 9099 | Cervical cancer | GCST90018597 | 1.23e-03 |
| 9100 | Triglyceride levels in large LDL | GCST90092866 | 1.23e-03 |
| 9101 | GM2A levels | GCST90469365 | 1.23e-03 |
| 9102 | Diverticulosis and diverticulitis | digestive | UKBB00000191 | 1.23e-03 |
| 9103 | Endometrial cancer | GCST006464 | 1.22e-03 |
| 9104 | OGFR levels | GCST90470118 | 1.22e-03 |
| 9105 | Coronary atherosclerosis | FING00000359 | 1.22e-03 |
| 9106 | Congenital malformations of heart and great arteries | FING00000336 | 1.22e-03 |
| 9107 | Triglycerides in medium HDL (UKB data field 23571) | GCST90269668 | 1.22e-03 |
| 9108 | PTN levels | GCST90470374 | 1.21e-03 |
| 9109 | CLEC1B/DKK1 ratio | GCST90314088 | 1.21e-03 |
| 9110 | CD58/ERBB3 ratio | GCST90313848 | 1.21e-03 |
| 9111 | Paroxysmal tachycardia | FING00001151 | 1.21e-03 |
| 9112 | GRPEL1/MME ratio | GCST90314992 | 1.21e-03 |
| 9113 | FUT8/VEGFC ratio | GCST90314896 | 1.21e-03 |
| 9114 | BCL2L2 levels | GCST90422077 | 1.20e-03 |
| 9115 | KYAT1 levels | GCST90469721 | 1.20e-03 |
| 9116 | Bone marrow fat fraction of right proximal femur | GCST90652393 | 1.20e-03 |
| 9117 | ITGB1/SELP ratio | GCST90315230 | 1.20e-03 |
| 9118 | Linoleic acid to total fatty acids percentage | GCST90502025 | 1.20e-03 |
| 9119 | Diverticulosis | digestive | UKBB00000190 | 1.20e-03 |
| 9120 | DTI autoptx L2 unc l tract | GCST90385191 | 1.20e-03 |
| 9121 | ADA2/COMP ratio | GCST90313166 | 1.20e-03 |
| 9122 | ICD10 N87: Dysplasia of cervix uteri | GCST90454218 | 1.19e-03 |
| 9123 | Total triglycerides levels | GCST003664 | 1.19e-03 |
| 9124 | Brainstem global volume Midbrain | GCST90002767 | 1.19e-03 |
| 9125 | CST3/TFF3 ratio | GCST90314299 | 1.19e-03 |
| 9126 | Intestinal infectious diseases | FING00000689 | 1.18e-03 |
| 9127 | CD55/ITGB1 ratio | GCST90313846 | 1.18e-03 |
| 9128 | RWDD1 levels | GCST90470510 | 1.18e-03 |
| 9129 | DAPP1/PTPN6 ratio | GCST90314397 | 1.18e-03 |
| 9130 | DNPH1/NSFL1C ratio | GCST90314526 | 1.17e-03 |
| 9131 | Asthma | Chronic lower respiratory diseases | UKBB00000053 | 1.17e-03 |
| 9132 | Saturated fatty acids levels | GCST90502194 | 1.17e-03 |
| 9133 | CNST/PRKAR1A ratio | GCST90314161 | 1.17e-03 |
| 9134 | ADH4/SORD ratio | GCST90313196 | 1.17e-03 |
| 9135 | GSTA1/RBP5 ratio | GCST90314995 | 1.17e-03 |
| 9136 | Operative procedures - Primary repair of inguinal hernia using insert of prosthetic material | Summary Operations | UKBB00000587 | 1.16e-03 |
| 9137 | wg lh intensity-contrast caudalmiddlefrontal | GCST90003795 | 1.16e-03 |
| 9138 | Hyperthyroidism | GCST90319319 | 1.16e-03 |
| 9139 | CASP8/DDX58 ratio | GCST90313651 | 1.16e-03 |
| 9140 | HEXIM1/IPCEF1 ratio | GCST90315046 | 1.16e-03 |
| 9141 | Plasma 2-aminobutyrate levels in chronic kidney disease | GCST90264339 | 1.16e-03 |
| 9142 | PDGFA/VEGFC ratio | GCST90315622 | 1.16e-03 |
| 9143 | Varicose veins of lower extremities | Diseases of veins, lymphatic vessels and lymph nodes, not elsewhere classified | UKBB00000894 | 1.15e-03 |
| 9144 | FKBPL levels | GCST90469246 | 1.15e-03 |
| 9145 | IRAK4/VASH1 ratio | GCST90315201 | 1.15e-03 |
| 9146 | CD22/SEMA7A ratio | GCST90313759 | 1.14e-03 |
| 9147 | IDP dMRI TBSS L1 Sagittal stratum L | GCST90004106 | 1.14e-03 |
| 9148 | LTA levels | GCST90469813 | 1.14e-03 |
| 9149 | B4GAT1 levels | GCST90468413 | 1.14e-03 |
| 9150 | Cholesterol in Medium LDL | GCST90498703 | 1.14e-03 |
| 9151 | High light scatter reticulocyte percentage of red cells | GCST90002386 | 1.14e-03 |
| 9152 | IL1R2/MEGF9 ratio | GCST90315159 | 1.13e-03 |
| 9153 | Gamma-CEHC glucuronide levels | GCST90199941 | 1.13e-03 |
| 9154 | FCER2/TREML2 ratio | GCST90314792 | 1.13e-03 |
| 9155 | Eosinophill count | Blood count | UKBB00000206 | 1.13e-03 |
| 9156 | PTGDS levels | GCST90470368 | 1.13e-03 |
| 9157 | 1-palmitoyl-2-oleoyl-GPE (16:0/18:1) metabolite level | GCST90616403 | 1.13e-03 |
| 9158 | NIT2 levels | GCST90470051 | 1.13e-03 |
| 9159 | DTI TBSS FA Anterior corona radiata R | GCST90384402 | 1.12e-03 |
| 9160 | Platelet count during first trimester of pregnancy | GCST90302224 | 1.12e-03 |
| 9161 | MEGF9 levels | GCST90469884 | 1.12e-03 |
| 9162 | CANT1/NUDT5 ratio | GCST90313619 | 1.12e-03 |
| 9163 | Alanine aminotransferase | Blood biochemistry | UKBB00000018 | 1.11e-03 |
| 9164 | Spondylopathies | FING00001325 | 1.11e-03 |
| 9165 | FOLH1 levels | GCST90469258 | 1.11e-03 |
| 9166 | HSDL2 levels | GCST90469485 | 1.11e-03 |
| 9167 | Right-hemisphere limbic network to hippocampus white-matter structural connectivity | GCST90302831 | 1.11e-03 |
| 9168 | IGFBP6/MFAP5 ratio | GCST90315135 | 1.11e-03 |
| 9169 | MANF/TXNDC5 ratio | GCST90315370 | 1.10e-03 |
| 9170 | DARS1 levels | GCST90468947 | 1.10e-03 |
| 9171 | GOPC levels | GCST90469377 | 1.10e-03 |
| 9172 | Polyunsaturated fatty acid levels | GCST90502618 | 1.10e-03 |
| 9173 | ENO2/PRSS27 ratio | GCST90314666 | 1.10e-03 |
| 9174 | Atopic dermatitis | GCST90027161 | 1.10e-03 |
| 9175 | HippSubfield lh volume Whole-hippocampal-body | GCST90002687 | 1.10e-03 |
| 9176 | DAB2/ERBIN ratio | GCST90314361 | 1.10e-03 |
| 9177 | LRIG1 levels | GCST90469794 | 1.09e-03 |
| 9178 | PPM1B levels | GCST90470296 | 1.09e-03 |
| 9179 | DKK1/LGALS8 ratio | GCST90314472 | 1.09e-03 |
| 9180 | HS6ST1 levels | GCST90469479 | 1.09e-03 |
| 9181 | Sleep apnea | neurological | UKBB00000774 | 1.09e-03 |
| 9182 | CCL7 levels | GCST90468585 | 1.08e-03 |
| 9183 | BCR levels | GCST90468436 | 1.08e-03 |
| 9184 | IL6ST levels | GCST90469603 | 1.08e-03 |
| 9185 | IDP T1 SIENAX white normalised volume | GCST90002432 | 1.08e-03 |
| 9186 | Nontoxic uninodular goiter (PheCode 241.1) | GCST90475640 | 1.08e-03 |
| 9187 | Phospholipids to Total Lipids in Medium HDL percentage | GCST90498651 | 1.08e-03 |
| 9188 | LGALS4 levels | GCST90469762 | 1.08e-03 |
| 9189 | PDLIM7 levels | GCST90470198 | 1.08e-03 |
| 9190 | LBR/PSRC1 ratio | GCST90315300 | 1.08e-03 |
| 9191 | Psoriasis (PheCode 696.4) | GCST90476187 | 1.08e-03 |
| 9192 | DTI autoptx L1 cst l tract | GCST90385147 | 1.07e-03 |
| 9193 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T481 | ECGU000481 | 1.07e-03 |
| 9194 | Triglycerides | GCST002216 | 1.07e-03 |
| 9195 | IRAK1 levels | GCST90469627 | 1.07e-03 |
| 9196 | Ischaemic heart disease, wide definition | FING00000703 | 1.07e-03 |
| 9197 | PDGFB/UXS1 ratio | GCST90315634 | 1.07e-03 |
| 9198 | KDR levels | GCST90469672 | 1.07e-03 |
| 9199 | Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T104 | ECGA000104 | 1.07e-03 |
| 9200 | SMAD3 levels | GCST90470677 | 1.06e-03 |
| 9201 | Polyunsaturated fatty acid levels | GCST90502607 | 1.06e-03 |
| 9202 | FUT8/SPARC ratio | GCST90314893 | 1.06e-03 |
| 9203 | AGER levels | GCST90012054 | 1.06e-03 |
| 9204 | NCR3LG1 levels | GCST90470010 | 1.06e-03 |
| 9205 | BIN2 levels | GCST90468445 | 1.06e-03 |
| 9206 | ADAMTS15 levels | GCST90468223 | 1.06e-03 |
| 9207 | FABP3 levels | GCST90469175 | 1.06e-03 |
| 9208 | Asthma | respiratory | UKBB00000054 | 1.06e-03 |
| 9209 | IDP dMRI ProbtrackX MD atr r | GCST90004222 | 1.06e-03 |
| 9210 | Lymphoid neoplasms | GCST90624743 | 1.06e-03 |
| 9211 | REST UKBBICA NET100 1212 | GCST90387066 | 1.06e-03 |
| 9212 | TOMM20 levels | GCST90470931 | 1.06e-03 |
| 9213 | MYL3 levels | GCST90469977 | 1.06e-03 |
| 9214 | BIN2/FYB1 ratio | GCST90313505 | 1.05e-03 |
| 9215 | CD300LG/CLEC14A ratio | GCST90313801 | 1.05e-03 |
| 9216 | IDI2 levels | GCST90469505 | 1.05e-03 |
| 9217 | CCL17/GRK5 ratio | GCST90313687 | 1.05e-03 |
| 9218 | Hemoglobin | GCST90018737 | 1.05e-03 |
| 9219 | Triacylglycerol_46:5_[M+NH4]1+ levels | GCST90060356 | 1.04e-03 |
| 9220 | Primary biliary cholangitis (PBC) | FING00001211 | 1.04e-03 |
| 9221 | HSPB6 levels | GCST90469490 | 1.04e-03 |
| 9222 | Saturated fatty acids to total fatty acids percentage | GCST90502701 | 1.04e-03 |
| 9223 | Myocardial fractal dimension (slice 7) | GCST90000293 | 1.04e-03 |
| 9224 | CCN3/FAP ratio | GCST90313721 | 1.04e-03 |
| 9225 | Linoleic acid levels | GCST90502004 | 1.04e-03 |
| 9226 | STAB2 levels | GCST90470755 | 1.04e-03 |
| 9227 | Diabetes (weighted GWA) | GCST90267279 | 1.04e-03 |
| 9228 | FGF21/LEP ratio | GCST90314810 | 1.03e-03 |
| 9229 | T2 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 6) | GCST90320825 | 1.03e-03 |
| 9230 | Bilirubin (E,Z or Z,E) levels | GCST90243750 | 1.03e-03 |
| 9231 | IGFBP6 levels | GCST90469531 | 1.03e-03 |
| 9232 | KIT levels | GCST90469692 | 1.02e-03 |
| 9233 | CNDP1/EGFR ratio | GCST90314146 | 1.02e-03 |
| 9234 | PFKFB2/SRP14 ratio | GCST90315650 | 1.02e-03 |
| 9235 | IL16 levels | GCST90241596 | 1.02e-03 |
| 9236 | Left-hemisphere dorsal attention network to right-hemisphere visual network white-matter structural connectivity | GCST90302694 | 1.02e-03 |
| 9237 | PPP1R12A levels | GCST90470300 | 1.02e-03 |
| 9238 | TXNDC5 levels | GCST90470991 | 1.01e-03 |
| 9239 | Hippocampal subfield left CA3 volume (body) | GCST90267940 | 1.01e-03 |
| 9240 | High density lipoprotein cholesterol levels | GCST90239651 | 1.01e-03 |
| 9241 | CDC26 levels | GCST90468663 | 1.01e-03 |
| 9242 | DTI TBSS MD Fornix cres+Stria terminalis R | GCST90384610 | 1.01e-03 |
| 9243 | Nasal polyps (PheCode 471) | GCST90476019 | 1.01e-03 |
| 9244 | ENG/NOTCH1 ratio | GCST90314648 | 1.01e-03 |
| 9245 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T16 | ECGU000016 | 1.01e-03 |
| 9246 | UXS1 levels | GCST90471023 | 1.00e-03 |
| 9247 | CCN1/DNAJB1 ratio | GCST90313709 | 1.00e-03 |
| 9248 | SRC/STAT5B ratio | GCST90315882 | 1.00e-03 |
| 9249 | TNFSF8 levels | GCST90470923 | 1.00e-03 |
| 9250 | DLL4 levels | GCST90469005 | 9.96e-04 |
| 9251 | GAPDH levels | GCST90469302 | 9.96e-04 |
| 9252 | F11 levels | GCST90469165 | 9.96e-04 |
| 9253 | FUT3 levels | GCST90241216 | 9.96e-04 |
| 9254 | Free cholesterol in large VLDL | GCST90498185 | 9.95e-04 |
| 9255 | SCPEP1 levels | GCST90470553 | 9.94e-04 |
| 9256 | Urate levels | GCST001791 | 9.94e-04 |
| 9257 | Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T107 | ECGA000107 | 9.91e-04 |
| 9258 | Linoleic acid levels | GCST90502295 | 9.90e-04 |
| 9259 | Colitis, primary sclerosing, strict definition | FING00000313 | 9.88e-04 |
| 9260 | FHIT/PARK7 ratio | GCST90314821 | 9.87e-04 |
| 9261 | Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T116 | ECGA000116 | 9.85e-04 |
| 9262 | Chronic Kidney Disease, Stage IV (PheCode 585.34) | GCST90476130 | 9.84e-04 |
| 9263 | EFNA4/TNFRSF9 ratio | GCST90314606 | 9.83e-04 |
| 9264 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T17 | ECGU000017 | 9.83e-04 |
| 9265 | Chronic iridocyclitis | FING00000287 | 9.80e-04 |
| 9266 | T1 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 74) | GCST90320637 | 9.79e-04 |
| 9267 | DNMBP/PTPN1 ratio | GCST90314517 | 9.78e-04 |
| 9268 | IDP T1 FAST ROIs V cerebellum VI | GCST90002567 | 9.77e-04 |
| 9269 | HPCAL1/PMVK ratio | GCST90315076 | 9.77e-04 |
| 9270 | Psoriasis vulgaris (PheCode 696.41) | GCST90476190 | 9.76e-04 |
| 9271 | EDAR levels | GCST90425556 | 9.75e-04 |
| 9272 | Varicose veins of lower extremity | circulatory system | UKBB00000895 | 9.74e-04 |
| 9273 | T1 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 57) | GCST90320620 | 9.72e-04 |
| 9274 | LAT/SPARC ratio | GCST90315288 | 9.72e-04 |
| 9275 | GFRA1/TNFRSF1A ratio | GCST90314924 | 9.71e-04 |
| 9276 | NTRK2 levels | GCST90470097 | 9.70e-04 |
| 9277 | Left-hemisphere default mode network to right-hemisphere visual network white-matter structural connectivity | GCST90302760 | 9.66e-04 |
| 9278 | Fatty acid(20:3)_[M-H]1- levels | GCST90060117 | 9.64e-04 |
| 9279 | Peripheral artery disease | GCST90018670 | 9.63e-04 |
| 9280 | VPS37A levels | GCST90471046 | 9.62e-04 |
| 9281 | Asthma | GCST006862 | 9.62e-04 |
| 9282 | Type 2 diabetes | GCST90086072 | 9.61e-04 |
| 9283 | Parental longevity (father's age at death) | GCST006700 | 9.60e-04 |
| 9284 | PDIA4 levels | GCST90470195 | 9.58e-04 |
| 9285 | CD99/MMP3 ratio | GCST90313928 | 9.58e-04 |
| 9286 | Malignant neoplasm of rectum, excluding all cancers (controls excluding all cancers) | FING00000771 | 9.56e-04 |
| 9287 | Total lipids in IDL | GCST90497594 | 9.55e-04 |
| 9288 | MAP2K6 levels | GCST90469852 | 9.52e-04 |
| 9289 | Gout (PheCode 274.1) | GCST90475735 | 9.52e-04 |
| 9290 | HippSubfield lh volume subiculum-head | GCST90002671 | 9.45e-04 |
| 9291 | SLMAP levels | GCST90470673 | 9.42e-04 |
| 9292 | DNAJC21 levels | GCST90469016 | 9.42e-04 |
| 9293 | ABL1/DNMBP ratio | GCST90313149 | 9.41e-04 |
| 9294 | DTI TBSS FA Sagittal stratum L | GCST90384411 | 9.41e-04 |
| 9295 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T120 | ECGU000120 | 9.38e-04 |
| 9296 | CCL2/CCL7 ratio | GCST90313696 | 9.38e-04 |
| 9297 | PM20D1 levels | GCST90470268 | 9.36e-04 |
| 9298 | FOLR3/KLK8 ratio | GCST90314868 | 9.36e-04 |
| 9299 | ADAM23 levels | GCST90240922 | 9.35e-04 |
| 9300 | Irregular menses | FING00000701 | 9.33e-04 |
| 9301 | COL5A1 levels | GCST90468820 | 9.32e-04 |
| 9302 | SLITRK1 levels | GCST90470669 | 9.29e-04 |
| 9303 | Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T67 | ECGA000067 | 9.29e-04 |
| 9304 | Linoleic acid levels | GCST90502306 | 9.28e-04 |
| 9305 | Primary biliary cholangitis | GCST003129 | 9.27e-04 |
| 9306 | PSME2 levels | GCST90470361 | 9.27e-04 |
| 9307 | SIGLEC1/SSC5D ratio | GCST90315844 | 9.25e-04 |
| 9308 | GZMA/IL12A_IL12B ratio | GCST90315009 | 9.25e-04 |
| 9309 | mean corpuscular volume (MCV, maximum, inv-norm transformed) | GCST90475466 | 9.24e-04 |
| 9310 | 1-(1-enyl-palmitoyl)-GPC (p-16:0) levels | GCST90199899 | 9.24e-04 |
| 9311 | RFC4 levels | GCST90470460 | 9.22e-04 |
| 9312 | SCRN1 levels | GCST90470556 | 9.19e-04 |
| 9313 | IDP dMRI TBSS ICVF Cingulum hippocampus R | GCST90004363 | 9.19e-04 |
| 9314 | CD79B/CKAP4 ratio | GCST90313898 | 9.18e-04 |
| 9315 | Alanine aminotransferase levels | GCST90278617 | 9.17e-04 |
| 9316 | Autorefraction - 6mm strong meridian angle (left) | Eyesight | UKBB00000077 | 9.16e-04 |
| 9317 | CREG1 levels | GCST90468857 | 9.16e-04 |
| 9318 | Other obstetric trauma | FING00001082 | 9.16e-04 |
| 9319 | SERPINH1 levels | GCST90470601 | 9.15e-04 |
| 9320 | MEP1B levels | GCST90469888 | 9.14e-04 |
| 9321 | Abnormal results of function study of liver (PheCode 573.7) | GCST90476097 | 9.13e-04 |
| 9322 | LPCAT2/SERPINB8 ratio | GCST90315328 | 9.13e-04 |
| 9323 | LGALS1 levels | GCST90469759 | 9.08e-04 |
| 9324 | CA4/PECAM1 ratio | GCST90313586 | 9.05e-04 |
| 9325 | Left-hemisphere control network to right-hemisphere dorsal attention network white-matter structural connectivity | GCST90302747 | 9.02e-04 |
| 9326 | Total fatty acid levels | GCST90502212 | 9.01e-04 |
| 9327 | CEP85 levels | GCST90468716 | 9.01e-04 |
| 9328 | Cancer code, self-reported: prostate cancer (UKB data field 20001_1044) | GCST90041905 | 9.00e-04 |
| 9329 | LAT2/SDC4 ratio | GCST90315278 | 8.96e-04 |
| 9330 | FCRL5/LY96 ratio | GCST90314803 | 8.95e-04 |
| 9331 | EVI5 levels | GCST90469158 | 8.95e-04 |
| 9332 | Lung cancer in never smokers | GCST90277434 | 8.94e-04 |
| 9333 | Saturated fatty acids levels | GCST90502675 | 8.93e-04 |
| 9334 | CD27/DLL1 ratio | GCST90313771 | 8.92e-04 |
| 9335 | Idiopathic pulmonary fibrosis | FING00000659 | 8.92e-04 |
| 9336 | GP1BA/SIAE ratio | GCST90314959 | 8.91e-04 |
| 9337 | Anomalies of dental arch relationship, including avohilmo | FING00000091 | 8.89e-04 |
| 9338 | Microalbumin urine | GCST90278639 | 8.87e-04 |
| 9339 | eosinophil (absolute count, maximum, inv-norm transformed) | GCST90475288 | 8.86e-04 |
| 9340 | CTSE levels | GCST90468911 | 8.85e-04 |
| 9341 | Acute renal failure | FING00000030 | 8.85e-04 |
| 9342 | BA-exvivo rh area perirhinal | GCST90003233 | 8.85e-04 |
| 9343 | CRELD2/ERP44 ratio | GCST90314253 | 8.82e-04 |
| 9344 | MAP3K5/MAVS ratio | GCST90315379 | 8.79e-04 |
| 9345 | IL34 levels | GCST90469593 | 8.77e-04 |
| 9346 | ITGB1 levels | GCST90469643 | 8.77e-04 |
| 9347 | Treatment or medication use - rosuvastatin (UKB data field 20003_1141192410) | GCST90042539 | 8.75e-04 |
| 9348 | ANXA11 levels | GCST90468315 | 8.75e-04 |
| 9349 | DTI TBSS L1 Cingulum cingulate gyrus L | GCST90384463 | 8.72e-04 |
| 9350 | EGFLAM levels | GCST90469084 | 8.71e-04 |
| 9351 | Asthma-related acute respiratory infections | FING00000117 | 8.71e-04 |
| 9352 | PLPBP levels | GCST90470260 | 8.69e-04 |
| 9353 | IDP T1 SIENAX white unnormalised volume | GCST90002433 | 8.69e-04 |
| 9354 | Polyunsaturated fatty acids to total fatty acids percentage | GCST90499302 | 8.68e-04 |
| 9355 | IGSF21 levels | GCST90469538 | 8.67e-04 |
| 9356 | CD27/NBL1 ratio | GCST90313774 | 8.67e-04 |
| 9357 | Eosinophill count (UKB data field 30150) | GCST90468068 | 8.66e-04 |
| 9358 | CCL4 levels | GCST004433 | 8.65e-04 |
| 9359 | MZT1 levels | GCST90469988 | 8.63e-04 |
| 9360 | SIAE/SNAP29 ratio | GCST90315843 | 8.61e-04 |
| 9361 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T23 | ECGU000023 | 8.60e-04 |
| 9362 | PAXX levels | GCST90470161 | 8.59e-04 |
| 9363 | Phospholipids in large LDL | GCST90498049 | 8.56e-04 |
| 9364 | End-diastolic bi-ventricular shape (principal component 8) | GCST90448487 | 8.56e-04 |
| 9365 | PILRA/TNFRSF1A ratio | GCST90315655 | 8.55e-04 |
| 9366 | Cholesterol in IDL | GCST90497501 | 8.55e-04 |
| 9367 | Sphingomyelin (d18:1/22:2, d18:2/22:1, d16:1/24:2) levels | GCST90200013 | 8.53e-04 |
| 9368 | NRCAM/NTRK2 ratio | GCST90315552 | 8.53e-04 |
| 9369 | T1 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 60) | GCST90320623 | 8.53e-04 |
| 9370 | TNFRSF4 levels | GCST90470913 | 8.51e-04 |
| 9371 | 5alpha-pregnan-3beta,20alpha-diol monosulfate (2) levels | GCST90199854 | 8.51e-04 |
| 9372 | Concentration of small LDL particles | GCST90499660 | 8.51e-04 |
| 9373 | DCN levels | GCST90468956 | 8.50e-04 |
| 9374 | Allergic disease (asthma, hay fever or eczema) | GCST005038 | 8.49e-04 |
| 9375 | Varicose veins | circulatory system | UKBB00000893 | 8.49e-04 |
| 9376 | Sphingomyelin (d17:1/16:0, d18:1/15:0, d16:1/17:0) levels | GCST90200017 | 8.49e-04 |
| 9377 | wg lh intensity-contrast middletemporal | GCST90003806 | 8.49e-04 |
| 9378 | Malignant neoplasm of bladder (PheCode 189.21) | GCST90475599 | 8.48e-04 |
| 9379 | PROS1 levels | GCST90470337 | 8.48e-04 |
| 9380 | QSOX1 levels | GCST90470402 | 8.46e-04 |
| 9381 | Free cholesterol in IDL | GCST90497564 | 8.45e-04 |
| 9382 | Coronary artery plaque burden | GCST90503075 | 8.45e-04 |
| 9383 | Alanine aminotransferase levels | GCST90025979 | 8.45e-04 |
| 9384 | Placental weight (paternal genotype, adjusted for sex) | GCST90275199 | 8.44e-04 |
| 9385 | Other malignant neoplasms of skin (=non-melanoma skin cancer), excluding all cancers (controls excluding all cancers) | FING00001067 | 8.43e-04 |
| 9386 | Plasma iron levels | GCST90100546 | 8.42e-04 |
| 9387 | potassium (maximum, inv-norm transformed) | GCST90476304 | 8.42e-04 |
| 9388 | COL28A1 levels | GCST90468815 | 8.39e-04 |
| 9389 | CDON/SCARA5 ratio | GCST90313995 | 8.39e-04 |
| 9390 | TXNL1 levels | GCST90470993 | 8.38e-04 |
| 9391 | WFIKKN2 levels | GCST90471077 | 8.38e-04 |
| 9392 | TIMM10 levels | GCST90470867 | 8.35e-04 |
| 9393 | X-12749 levels | GCST90243770 | 8.34e-04 |
| 9394 | Cholesterol to total lipids in small VLDL percentage (UKB data field 23600) | GCST90269697 | 8.34e-04 |
| 9395 | CDH3/TNFRSF21 ratio | GCST90313953 | 8.32e-04 |
| 9396 | RNF41 levels | GCST90470485 | 8.32e-04 |
| 9397 | Sphingomyelin_40:3_[M+H]1+ levels | GCST90060348 | 8.31e-04 |
| 9398 | Cholesteryl esters in medium LDL (UKB data field 23541) | GCST90269638 | 8.30e-04 |
| 9399 | Other embolism and thrombosis | FING00001043 | 8.29e-04 |
| 9400 | SLAMF1 levels | GCST90274835 | 8.28e-04 |
| 9401 | Omega-6 fatty acid levels | GCST90502519 | 8.28e-04 |
| 9402 | Autorefraction - 3mm strong meridian angle (right) | Eyesight | UKBB00000068 | 8.28e-04 |
| 9403 | TMED8 levels | GCST90470885 | 8.25e-04 |
| 9404 | ESAM/VSIR ratio | GCST90314721 | 8.24e-04 |
| 9405 | MYOC levels | GCST90469983 | 8.22e-04 |
| 9406 | L3HYPDH levels | GCST90469724 | 8.19e-04 |
| 9407 | Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T113 | ECGA000113 | 8.19e-04 |
| 9408 | Pregnenediol disulfate (C21H34O8S2) levels | GCST90199840 | 8.17e-04 |
| 9409 | CCL18 levels | GCST90468570 | 8.15e-04 |
| 9410 | FHIT/MAX ratio | GCST90314818 | 8.15e-04 |
| 9411 | PMM2 levels | GCST90470270 | 8.14e-04 |
| 9412 | Cholesteryl Esters to Total Lipids in Small LDL percentage | GCST90499595 | 8.13e-04 |
| 9413 | End-diastolic bi-ventricular shape (principal component 3) | GCST90448482 | 8.13e-04 |
| 9414 | TREML2 levels | GCST90470962 | 8.13e-04 |
| 9415 | Cerebrospinal fluid sulfate* levels | GCST90318056 | 8.10e-04 |
| 9416 | CLEC4G/SEMA3F ratio | GCST90314123 | 8.10e-04 |
| 9417 | Acute appendicitis, no complications | FING00000018 | 8.09e-04 |
| 9418 | TOP2B levels | GCST90470934 | 8.08e-04 |
| 9419 | CD99/PIK3IP1 ratio | GCST90313929 | 8.08e-04 |
| 9420 | Infections of the skin and subcutaneous tissue | FING00000670 | 8.08e-04 |
| 9421 | SIAE levels | GCST90470629 | 8.06e-04 |
| 9422 | Secondary hypothyroidism (PheCode 244.1) | GCST90475649 | 8.06e-04 |
| 9423 | Eye problems/disorders - Cataract | Eyesight | UKBB00000230 | 8.05e-04 |
| 9424 | PAM levels | GCST90470156 | 8.05e-04 |
| 9425 | CRACR2A levels | GCST90468853 | 8.04e-04 |
| 9426 | CTSO/IGF2R ratio | GCST90314317 | 8.04e-04 |
| 9427 | CA3/HMBS ratio | GCST90313584 | 8.02e-04 |
| 9428 | FCRL5/TNFRSF13B ratio | GCST90314805 | 8.02e-04 |
| 9429 | Total Lipids in VLDL | GCST90500234 | 8.02e-04 |
| 9430 | DKK4 levels | GCST90468999 | 8.02e-04 |
| 9431 | Ischemic stroke | GCST90018644 | 8.02e-04 |
| 9432 | PPIF levels | GCST90470293 | 8.00e-04 |
| 9433 | Metabolic syndrome | GCST90444489 | 7.97e-04 |
| 9434 | FCGR2A/FCGR2B ratio | GCST90314793 | 7.97e-04 |
| 9435 | Illnesses of father - Lung cancer | Family history | UKBB00000344 | 7.96e-04 |
| 9436 | Other benign neoplasms of skin | FING00000971 | 7.96e-04 |
| 9437 | RETN levels | GCST90012034 | 7.95e-04 |
| 9438 | Immature fraction of reticulocytes | GCST004628 | 7.94e-04 |
| 9439 | Illnesses of mother - None of the above (group 1) | Family history | UKBB00000349 | 7.92e-04 |
| 9440 | Degree of unsaturation | GCST90502231 | 7.91e-04 |
| 9441 | Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T129 | ECGA000129 | 7.89e-04 |
| 9442 | ThalamNuclei rh volume MDl | GCST90002748 | 7.89e-04 |
| 9443 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T18 | ECGU000018 | 7.86e-04 |
| 9444 | IDP dMRI ProbtrackX FA cgc r | GCST90003930 | 7.84e-04 |
| 9445 | LSIL lesion of the cervix uteri | FING00000732 | 7.83e-04 |
| 9446 | Total lipids in medium HDL (UKB data field 23566) | GCST90269663 | 7.82e-04 |
| 9447 | SNCA levels | GCST90470694 | 7.82e-04 |
| 9448 | Thyrotoxicosis | FING00001360 | 7.81e-04 |
| 9449 | Placental weight (paternal genotype, adjusted for sex and gestational age) | GCST90275191 | 7.81e-04 |
| 9450 | PCYT2 levels | GCST90470178 | 7.81e-04 |
| 9451 | ICAM3/LY9 ratio | GCST90315121 | 7.80e-04 |
| 9452 | APOB levels | GCST90497137 | 7.80e-04 |
| 9453 | BMP6 levels | GCST90468454 | 7.79e-04 |
| 9454 | Other demyelinating diseases of the central nervous system | FING00000995 | 7.79e-04 |
| 9455 | Lysophosphatidylcholine (26:0) [sn2] levels | GCST90024189 | 7.77e-04 |
| 9456 | CST5 levels | GCST90468895 | 7.76e-04 |
| 9457 | Red blood cell count | GCST90018751 | 7.76e-04 |
| 9458 | Plasma X-24947 levels in chronic kidney disease | GCST90266816 | 7.75e-04 |
| 9459 | AP3B1 levels | GCST90468325 | 7.74e-04 |
| 9460 | Disorders of vestibular function (Vertigo) | FING00000464 | 7.73e-04 |
| 9461 | Waist-to-hip ratio adjusted for BMI | GCST012230 | 7.72e-04 |
| 9462 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T88 | ECGU000088 | 7.72e-04 |
| 9463 | DAB2/ZBTB16 ratio | GCST90314370 | 7.70e-04 |
| 9464 | IDP dMRI TBSS L3 Posterior limb of internal capsule R | GCST90004189 | 7.70e-04 |
| 9465 | rfMRI amplitudes (ICA100 node 27) | GCST90004615 | 7.69e-04 |
| 9466 | GALNT10/SEMA7A ratio | GCST90314915 | 7.67e-04 |
| 9467 | Triacylglycerol_51:4_[M+NH4]1+ levels | GCST90060491 | 7.67e-04 |
| 9468 | TBCA levels | GCST90470812 | 7.65e-04 |
| 9469 | 3-methyl-2-oxobutyrate levels | GCST90199677 | 7.64e-04 |
| 9470 | CTSF/NAAA ratio | GCST90314314 | 7.64e-04 |
| 9471 | Bone density Z-score | GCST90278621 | 7.63e-04 |
| 9472 | PPY levels | GCST90470309 | 7.62e-04 |
| 9473 | CRTAP levels | GCST90468872 | 7.62e-04 |
| 9474 | Left ventricular end systole anterior wall thickness | GCST90278512 | 7.61e-04 |
| 9475 | TNFRSF14/TNFSF14 ratio | GCST90315936 | 7.61e-04 |
| 9476 | Lysophosphatidylcholine (26:0) [sn1] levels | GCST90025427 | 7.61e-04 |
| 9477 | Sequelae of cerebrovascular disease | FING00001294 | 7.58e-04 |
| 9478 | CC2D1A/WWP2 ratio | GCST90313668 | 7.58e-04 |
| 9479 | Aortic aneurysm (PheCode 442.1) | GCST90475993 | 7.57e-04 |
| 9480 | CD40LG/EREG ratio | GCST90313820 | 7.56e-04 |
| 9481 | Primary sclerosing cholangitis | GCST004030 | 7.54e-04 |
| 9482 | AGER levels | GCST90468252 | 7.53e-04 |
| 9483 | Triglycerides to Total Lipids in Medium VLDL percentage | GCST90499069 | 7.53e-04 |
| 9484 | Other hypertrophic and atrophic conditions (PheCode 701) | GCST90476197 | 7.49e-04 |
| 9485 | Cholesteryl Esters to Total Lipids in Very Large VLDL percentage | GCST90500569 | 7.49e-04 |
| 9486 | CD84/VASH1 ratio | GCST90313920 | 7.49e-04 |
| 9487 | NUMB levels | GCST90470108 | 7.47e-04 |
| 9488 | CDHR1 levels | GCST90468678 | 7.46e-04 |
| 9489 | CTSF/CTSV ratio | GCST90314313 | 7.46e-04 |
| 9490 | Thick vs thin eyebrows | GCST006093 | 7.46e-04 |
| 9491 | FHIT levels | GCST90469238 | 7.45e-04 |
| 9492 | HMOX2/TDRKH ratio | GCST90315067 | 7.45e-04 |
| 9493 | Red blood cell count | GCST90278641 | 7.41e-04 |
| 9494 | triglyceride (mean, inv-norm transformed) | GCST90476433 | 7.40e-04 |
| 9495 | DFFA levels | GCST90468987 | 7.40e-04 |
| 9496 | Free Cholesterol to Total Lipids in Medium HDL percentage | GCST90498580 | 7.40e-04 |
| 9497 | Percentage of monosialylation of core-fucosylated monogalactosylated structures without bisecting GlcNAc (GP41) | GCST90668485 | 7.40e-04 |
| 9498 | Phospholipids to Total Lipids in IDL percentage | GCST90497642 | 7.38e-04 |
| 9499 | CST3/RARRES2 ratio | GCST90314295 | 7.37e-04 |
| 9500 | LAT/PDGFA ratio | GCST90315285 | 7.36e-04 |
| 9501 | Triglycerides to Total Lipids in Very Large HDL percentage | GCST90500508 | 7.34e-04 |
| 9502 | total cholesterol (maximum, inv-norm transformed) | GCST90476418 | 7.33e-04 |
| 9503 | NUDT5 levels | GCST90470107 | 7.33e-04 |
| 9504 | MYO9B levels | GCST90469982 | 7.32e-04 |
| 9505 | CCN2/TACC3 ratio | GCST90313717 | 7.31e-04 |
| 9506 | Subpubic angle | GCST90448908 | 7.29e-04 |
| 9507 | Gastroduodenal ulcer | FING00000565 | 7.28e-04 |
| 9508 | Clonal hematopoiesis (DNMT3A mutation) | GCST90435354 | 7.28e-04 |
| 9509 | BAX/MAX ratio | GCST90313466 | 7.28e-04 |
| 9510 | REST UKBBICA NODEamps25 0014 | GCST90385497 | 7.27e-04 |
| 9511 | Percentage of M9 (GP18) | GCST90668462 | 7.27e-04 |
| 9512 | Disorders of synovium and tendon | FING00000462 | 7.26e-04 |
| 9513 | Triglycerides in medium LDL | GCST90498870 | 7.26e-04 |
| 9514 | CA13/QDPR ratio | GCST90313564 | 7.23e-04 |
| 9515 | Phospholipids in very small VLDL | GCST90500840 | 7.23e-04 |
| 9516 | Docosahexaenoic acid to total fatty acids percentage | GCST90502284 | 7.21e-04 |
| 9517 | KIFBP/TACC3 ratio | GCST90315249 | 7.21e-04 |
| 9518 | VAMP5 levels | GCST90471024 | 7.19e-04 |
| 9519 | MEPE levels | GCST90469889 | 7.18e-04 |
| 9520 | Hypothyroidism, strict autoimmune | FING00000656 | 7.18e-04 |
| 9521 | Sphingomyelin_38:1_[M+H]1+ levels | GCST90060306 | 7.16e-04 |
| 9522 | Diseases of middle ear and mastoid | FING00000427 | 7.16e-04 |
| 9523 | Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T64 | ECGA000064 | 7.16e-04 |
| 9524 | Gout and other crystal arthrop (PheCode 274) | GCST90475731 | 7.16e-04 |
| 9525 | DEFA1 or DEFA1B levels | GCST90468979 | 7.15e-04 |
| 9526 | RPN1 levels | GCST90240964 | 7.15e-04 |
| 9527 | TYRP1 levels | GCST90470998 | 7.14e-04 |
| 9528 | DUT levels | GCST90469054 | 7.13e-04 |
| 9529 | Total cholesterol minus HDL-C levels | GCST90499129 | 7.13e-04 |
| 9530 | Neoplasm of uncertain behavior (PheCode 199) | GCST90475606 | 7.13e-04 |
| 9531 | ENO2/RWDD1 ratio | GCST90314667 | 7.13e-04 |
| 9532 | PTS levels | GCST90470390 | 7.13e-04 |
| 9533 | Triglyceride levels in IDL | GCST90092841 | 7.12e-04 |
| 9534 | SERPINA6 levels | GCST90470586 | 7.12e-04 |
| 9535 | Occlusion and stenosis of precerebral arteries (PheCode 433.1) | GCST90475986 | 7.10e-04 |
| 9536 | NUDT5/SERPINB1 ratio | GCST90315581 | 7.10e-04 |
| 9537 | CTSD levels | GCST90468910 | 7.09e-04 |
| 9538 | FSTL1 levels | GCST90469271 | 7.09e-04 |
| 9539 | DYNLT1 levels | GCST90469057 | 7.08e-04 |
| 9540 | Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T106 | ECGA000106 | 7.08e-04 |
| 9541 | USO1 levels | GCST90471018 | 7.07e-04 |
| 9542 | ISLR2 levels | GCST90469629 | 7.06e-04 |
| 9543 | T1 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 6) | GCST90320569 | 7.06e-04 |
| 9544 | Plasma X-25279 levels in chronic kidney disease | GCST90266835 | 7.05e-04 |
| 9545 | Spinal stenosis | FING00001322 | 7.04e-04 |
| 9546 | Phospholipids to total lipids in IDL percentage (UKB data field 23609) | GCST90269706 | 7.03e-04 |
| 9547 | CDH3 levels | GCST90468674 | 7.03e-04 |
| 9548 | IDP dMRI TBSS OD Pontine crossing tract | GCST90004403 | 7.03e-04 |
| 9549 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T90 | ECGU000090 | 7.03e-04 |
| 9550 | CD300LG/DSG2 ratio | GCST90313802 | 7.03e-04 |
| 9551 | Nephritis and nephropathy without mention of glomerulonephritis (PheCode 580.3) | GCST90476115 | 7.01e-04 |
| 9552 | LGMN levels | GCST90469766 | 6.99e-04 |
| 9553 | Free Cholesterol to Total Lipids in Small HDL percentage | GCST90499436 | 6.97e-04 |
| 9554 | CD48/FCRL6 ratio | GCST90313840 | 6.97e-04 |
| 9555 | VSTM2L levels | GCST90471057 | 6.96e-04 |
| 9556 | GSTA3/KRT18 ratio | GCST90314997 | 6.96e-04 |
| 9557 | Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T10 | ECGA000010 | 6.96e-04 |
| 9558 | CSNK2A1 levels | GCST90468889 | 6.94e-04 |
| 9559 | High light scatter reticulocyte count | GCST90002385 | 6.93e-04 |
| 9560 | Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T110 | ECGA000110 | 6.93e-04 |
| 9561 | CBLIF levels | GCST90468552 | 6.89e-04 |
| 9562 | Triglycerides to Total Lipids in Small LDL percentage | GCST90499740 | 6.89e-04 |
| 9563 | TNFSF13B levels | GCST90470920 | 6.89e-04 |
| 9564 | HAVCR2 levels | GCST90469432 | 6.88e-04 |
| 9565 | Sphingomyelin (d18:1/14:0) levels/Sphingomyelin (d16:1/16:0) levels | GCST90025115 | 6.87e-04 |
| 9566 | Total lipids in large HDL | GCST90497818 | 6.87e-04 |
| 9567 | Polyunsaturated fatty acids to monounsaturated fatty acids ratio | GCST90502570 | 6.86e-04 |
| 9568 | Saturated fatty acids levels | GCST90502186 | 6.86e-04 |
| 9569 | 1-linoleoyl-GPI (18:2) levels | GCST90199821 | 6.85e-04 |
| 9570 | XPNPEP2 levels | GCST90471084 | 6.84e-04 |
| 9571 | B4GALT1/SPON2 ratio | GCST90313434 | 6.84e-04 |
| 9572 | CCL17/CD69 ratio | GCST90313684 | 6.84e-04 |
| 9573 | HippSubfield rh volume subiculum-head | GCST90002693 | 6.82e-04 |
| 9574 | Left ventricular end diastole inferolateral wall thickness | GCST90278516 | 6.81e-04 |
| 9575 | IDP dMRI TBSS MO Medial lemniscus R | GCST90003960 | 6.80e-04 |
| 9576 | XIAP levels | GCST90471083 | 6.80e-04 |
| 9577 | Cholesterol to Total Lipids in Very Large VLDL percentage | GCST90500539 | 6.77e-04 |
| 9578 | Hip width to body height ratio | GCST90270260 | 6.75e-04 |
| 9579 | BST2/MME ratio | GCST90313539 | 6.75e-04 |
| 9580 | Blood urea nitrogen levels | GCST90278623 | 6.74e-04 |
| 9581 | Triacylglycerol_51:2_[M+NH4]1+ levels | GCST90060497 | 6.73e-04 |
| 9582 | IDP dMRI TBSS FA Retrolenticular part of internal capsule L | GCST90003898 | 6.73e-04 |
| 9583 | Kynurenine levels | GCST90243477 | 6.73e-04 |
| 9584 | CLEC14A/EPHB4 ratio | GCST90314079 | 6.72e-04 |
| 9585 | LACTB2 levels | GCST90469726 | 6.69e-04 |
| 9586 | BLVRB/HBQ1 ratio | GCST90313525 | 6.67e-04 |
| 9587 | RSPO1/RSPO3 ratio | GCST90315790 | 6.67e-04 |
| 9588 | Placental weight (fetal genotype, adjusted for sex and gestational age) | GCST90275189 | 6.65e-04 |
| 9589 | NTRK3/SCARF2 ratio | GCST90315571 | 6.65e-04 |
| 9590 | MPIG6B/PDGFB ratio | GCST90315482 | 6.62e-04 |
| 9591 | Retinal detachments and defects (PheCode 361) | GCST90475845 | 6.60e-04 |
| 9592 | ZBTB17 levels | GCST90471096 | 6.60e-04 |
| 9593 | T2 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 109) | GCST90320928 | 6.58e-04 |
| 9594 | Operative procedures - Closed reduction of fracture of bone and fixation using nail or screw | Summary Operations | UKBB00000575 | 6.58e-04 |
| 9595 | Histidine levels | GCST90497481 | 6.57e-04 |
| 9596 | KLK8/WFDC12 ratio | GCST90315259 | 6.56e-04 |
| 9597 | CLEC1B/LGALS8 ratio | GCST90314096 | 6.55e-04 |
| 9598 | Polyunsaturated fatty acid levels | GCST90092939 | 6.53e-04 |
| 9599 | CCL11/CCL7 ratio | GCST90313673 | 6.53e-04 |
| 9600 | Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T118 | ECGA000118 | 6.52e-04 |
| 9601 | Mean arterial pressure | GCST90018743 | 6.52e-04 |
| 9602 | MAD1L1 levels | GCST90469836 | 6.52e-04 |
| 9603 | BCAN/NCAN ratio | GCST90313481 | 6.51e-04 |
| 9604 | LTB4R levels | GCST90422164 | 6.51e-04 |
| 9605 | COL24A1 levels | GCST90468814 | 6.51e-04 |
| 9606 | FADD/PLIN3 ratio | GCST90314772 | 6.50e-04 |
| 9607 | Ulcerative colitis | GCST90475322 | 6.49e-04 |
| 9608 | GZMH/KLRD1 ratio | GCST90315016 | 6.48e-04 |
| 9609 | Left-hemisphere dorsal attention network to putamen white-matter structural connectivity | GCST90302703 | 6.48e-04 |
| 9610 | ANXA4/FADD ratio | GCST90313291 | 6.46e-04 |
| 9611 | Varicose veins of lower extremity (PheCode 454.1) | GCST90476013 | 6.44e-04 |
| 9612 | HPCAL1/NUDC ratio | GCST90315074 | 6.41e-04 |
| 9613 | CCN3 levels | GCST90468589 | 6.41e-04 |
| 9614 | Blood cell traits latent factor 9 (white cell) | GCST90559251 | 6.40e-04 |
| 9615 | Cholesterol, total | GCST002221 | 6.39e-04 |
| 9616 | IL18 levels | GCST90428411 | 6.38e-04 |
| 9617 | APP/CCL28 ratio | GCST90313317 | 6.37e-04 |
| 9618 | Primary biliary cholangitis | GCST90061440 | 6.36e-04 |
| 9619 | CDSN levels | GCST90468688 | 6.35e-04 |
| 9620 | T1 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 91) | GCST90320654 | 6.35e-04 |
| 9621 | Mean corpuscular hemoglobin | GCST90002390 | 6.34e-04 |
| 9622 | CHAD levels | GCST90468737 | 6.34e-04 |
| 9623 | BAG6 levels | GCST90468418 | 6.33e-04 |
| 9624 | CST3/DEFA1_DEFA1B ratio | GCST90314291 | 6.32e-04 |
| 9625 | Oral glucose tolerance test-1h | GCST90566422 | 6.30e-04 |
| 9626 | NTF3 levels | GCST90470094 | 6.30e-04 |
| 9627 | PLXNA4/SKAP2 ratio | GCST90315685 | 6.30e-04 |
| 9628 | Free Cholesterol to Total Lipids in Chylomicrons and Extremely Large VLDL percentage | GCST90500992 | 6.30e-04 |
| 9629 | BCR/GOPC ratio | GCST90313491 | 6.30e-04 |
| 9630 | GADD45GIP1 levels | GCST90469293 | 6.29e-04 |
| 9631 | Spleen volume | GCST90016667 | 6.26e-04 |
| 9632 | Total lipids in medium HDL | GCST90498604 | 6.26e-04 |
| 9633 | SPRR3 levels | GCST90470737 | 6.26e-04 |
| 9634 | Total protein levels | GCST90025995 | 6.25e-04 |
| 9635 | Total fatty acid levels | GCST90500061 | 6.24e-04 |
| 9636 | IDP dMRI TBSS L2 Retrolenticular part of internal capsule L | GCST90004144 | 6.23e-04 |
| 9637 | ANXA1 levels | GCST90240296 | 6.23e-04 |
| 9638 | Cholesteryl Esters in HDL | GCST90497357 | 6.17e-04 |
| 9639 | Triacylglycerol_48:3_[M+NH4]1+ levels | GCST90060418 | 6.17e-04 |
| 9640 | ADH4/KRT18 ratio | GCST90313192 | 6.16e-04 |
| 9641 | SDC4/SELP ratio | GCST90315817 | 6.15e-04 |
| 9642 | IL6ST/LIFR ratio | GCST90315166 | 6.14e-04 |
| 9643 | Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T102 | ECGA000102 | 6.13e-04 |
| 9644 | FOLR3 levels | GCST90469261 | 6.13e-04 |
| 9645 | Myocardial infarction | GCST90018657 | 6.13e-04 |
| 9646 | ERBB2/PTPRF ratio | GCST90314688 | 6.12e-04 |
| 9647 | Saturated fatty acids to total fatty acids percentage | GCST90502207 | 6.12e-04 |
| 9648 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T85 | ECGU000085 | 6.12e-04 |
| 9649 | AXL levels | GCST90468406 | 6.10e-04 |
| 9650 | Total Cholesteryl ester levels | GCST90025188 | 6.10e-04 |
| 9651 | PSAP levels | GCST90426586 | 6.10e-04 |
| 9652 | IL32 levels | GCST90469591 | 6.08e-04 |
| 9653 | ADM levels | GCST90011996 | 6.08e-04 |
| 9654 | Alanine levels | GCST003666 | 6.07e-04 |
| 9655 | Triacylglycerol_46:4_[M+NH4]1+ levels | GCST90060362 | 6.07e-04 |
| 9656 | CLEC1B/EGF ratio | GCST90314089 | 6.07e-04 |
| 9657 | IL18BP levels | GCST90469564 | 6.06e-04 |
| 9658 | Rheumatoid arthritis (PheCode 714.1) | GCST90476230 | 6.06e-04 |
| 9659 | Nonalcoholic steatohepatitis | FING00000879 | 6.06e-04 |
| 9660 | CRACR2A/IRAG2 ratio | GCST90314227 | 6.05e-04 |
| 9661 | KRT18 levels | GCST90469716 | 6.05e-04 |
| 9662 | Recent feelings of tiredness or low energy | Depression | UKBB00000740 | 6.04e-04 |
| 9663 | Lymphocyte count | GCST004627 | 6.04e-04 |
| 9664 | Bone density T-score | GCST90278620 | 6.04e-04 |
| 9665 | Total lipids in very small VLDL | GCST90500813 | 6.03e-04 |
| 9666 | Saturated fatty acids to total fatty acids percentage | GCST90499966 | 6.02e-04 |
| 9667 | HLA-A levels | GCST90469457 | 6.01e-04 |
| 9668 | AmygNuclei lh volume Whole-amygdala | GCST90002657 | 6.01e-04 |
| 9669 | DCBLD2/PLA2G15 ratio | GCST90314428 | 6.01e-04 |
| 9670 | BLMH/PEAR1 ratio | GCST90313519 | 6.00e-04 |
| 9671 | ERP29 levels | GCST90469149 | 6.00e-04 |
| 9672 | Lymphoid neoplasms (drug group 1 phenocluster) | GCST90624740 | 6.00e-04 |
| 9673 | MRAP levels | GCST90089910 | 5.99e-04 |
| 9674 | CHMP1A/RHOC ratio | GCST90314053 | 5.97e-04 |
| 9675 | RRAS levels | GCST90470499 | 5.96e-04 |
| 9676 | HippSubfield lh volume GC-ML-DG-body | GCST90002681 | 5.96e-04 |
| 9677 | LRTM2 levels | GCST90469808 | 5.95e-04 |
| 9678 | TYRO3 levels | GCST90470997 | 5.94e-04 |
| 9679 | Malignant neoplasm, excluding all cancers (controls excluding all cancers) | FING00000780 | 5.94e-04 |
| 9680 | CD300E/LILRA5 ratio | GCST90313798 | 5.93e-04 |
| 9681 | Triacylglycerol_51:3_[M+NH4]1+ levels | GCST90060494 | 5.92e-04 |
| 9682 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T137 | ECGU000137 | 5.92e-04 |
| 9683 | CALCOCO1/CASP3 ratio | GCST90313596 | 5.92e-04 |
| 9684 | ARHGAP45 levels | GCST90468355 | 5.91e-04 |
| 9685 | DTI autoptx MD unc l tract | GCST90385245 | 5.90e-04 |
| 9686 | Triglyceride levels in LDL | GCST90092890 | 5.89e-04 |
| 9687 | BPIFA2 levels | GCST90468461 | 5.88e-04 |
| 9688 | CST3/IL18BP ratio | GCST90314294 | 5.88e-04 |
| 9689 | EDAR/ERBIN ratio | GCST90314575 | 5.87e-04 |
| 9690 | Osteoarthritis | GCST90468144 | 5.86e-04 |
| 9691 | 3-amino-2-piperidone levels | GCST90200188 | 5.84e-04 |
| 9692 | ITPA levels | GCST90469654 | 5.83e-04 |
| 9693 | Triacylglycerol_53:4_[M+NH4]1+ levels | GCST90060524 | 5.83e-04 |
| 9694 | N-acetylphenylalanine levels | GCST90200677 | 5.83e-04 |
| 9695 | ADGRG2/NRCAM ratio | GCST90313186 | 5.82e-04 |
| 9696 | Respiratory disease (confirmatory factor analysis Factor 11) | GCST90309345 | 5.81e-04 |
| 9697 | TNFRSF13B/TNFSF13B ratio | GCST90315933 | 5.81e-04 |
| 9698 | Total fatty acid levels | GCST90092987 | 5.77e-04 |
| 9699 | Dihexosylceramide (d18:1/22:0) levels | GCST90025348 | 5.76e-04 |
| 9700 | Cholesterol in Small LDL | GCST90499559 | 5.76e-04 |
| 9701 | DTI autoptx FA unc l tract | GCST90385137 | 5.75e-04 |
| 9702 | X-21286 levels | GCST90200562 | 5.75e-04 |
| 9703 | SRPK2 levels | GCST90470743 | 5.74e-04 |
| 9704 | DCTN1/FXN ratio | GCST90314430 | 5.73e-04 |
| 9705 | OMD/SOST ratio | GCST90315585 | 5.72e-04 |
| 9706 | AXL/MCAM ratio | GCST90313421 | 5.72e-04 |
| 9707 | Nonalcoholic fatty liver disease | FING00000878 | 5.71e-04 |
| 9708 | DAG1/SCARF1 ratio | GCST90314381 | 5.71e-04 |
| 9709 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T94 | ECGU000094 | 5.67e-04 |
| 9710 | MMP12 levels | GCST90469916 | 5.66e-04 |
| 9711 | Triacylglycerol_52:6_[M+NH4]1+ levels | GCST90060504 | 5.66e-04 |
| 9712 | CST6/FABP9 ratio | GCST90314301 | 5.65e-04 |
| 9713 | RGS10 levels | GCST90470465 | 5.65e-04 |
| 9714 | Triglycerides to Total Lipids in Medium LDL percentage | GCST90498885 | 5.64e-04 |
| 9715 | Polyunsaturated fatty acid levels | GCST90502134 | 5.64e-04 |
| 9716 | Right subiculum volume (body) | GCST90267980 | 5.64e-04 |
| 9717 | F2R/TMSB10 ratio | GCST90314738 | 5.64e-04 |
| 9718 | HARS1 levels | GCST90469430 | 5.62e-04 |
| 9719 | AMBN levels | GCST90468287 | 5.62e-04 |
| 9720 | IDP dMRI ProbtrackX FA ifo r | GCST90003938 | 5.62e-04 |
| 9721 | Peripheral vascular disease | GCST90475996 | 5.60e-04 |
| 9722 | Radial peak diastolic strain rate | GCST90019014 | 5.60e-04 |
| 9723 | ICAM2 levels | GCST90469499 | 5.60e-04 |
| 9724 | Other hypothyroidism | Disorders of thyroid gland | UKBB00000611 | 5.58e-04 |
| 9725 | LAIR1 levels | GCST90469728 | 5.58e-04 |
| 9726 | eosinophil (fraction, minimum, inv-norm transformed) | GCST90475303 | 5.55e-04 |
| 9727 | LAMP3/PRSS8 ratio | GCST90315275 | 5.54e-04 |
| 9728 | ANGPT1/APP ratio | GCST90313260 | 5.54e-04 |
| 9729 | Lung volume | GCST90016668 | 5.52e-04 |
| 9730 | GRP levels | GCST90469406 | 5.52e-04 |
| 9731 | Triacylglycerol_50:5_[M+NH4]1+ levels | GCST90060463 | 5.50e-04 |
| 9732 | IL1RL2 levels | GCST90469575 | 5.49e-04 |
| 9733 | SUSD1/THPO ratio | GCST90315899 | 5.49e-04 |
| 9734 | Hypothyroidism | endocrine/metabolic | UKBB00000335 | 5.49e-04 |
| 9735 | Triglycerides to total lipids in very large VLDL percentage (UKB data field 23588) | GCST90269685 | 5.48e-04 |
| 9736 | T2 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 87) | GCST90320906 | 5.48e-04 |
| 9737 | ITGB5/SIAE ratio | GCST90315234 | 5.46e-04 |
| 9738 | Cholesteryl esters to total lipids ratio in small HDL | GCST90092947 | 5.46e-04 |
| 9739 | Hyperlipidemia | GCST90090994 | 5.45e-04 |
| 9740 | SCGB3A1 levels | GCST90470542 | 5.45e-04 |
| 9741 | PLA2G4A/SNAP29 ratio | GCST90315669 | 5.45e-04 |
| 9742 | FLT3/FLT3LG ratio | GCST90314859 | 5.45e-04 |
| 9743 | RGMB levels | GCST90470464 | 5.44e-04 |
| 9744 | APOM levels | GCST90468342 | 5.44e-04 |
| 9745 | ART3/RGMA ratio | GCST90313362 | 5.41e-04 |
| 9746 | Mean corpuscular haemoglobin (UKB data field 30050) | GCST90468084 | 5.40e-04 |
| 9747 | Lymphoid neoplasms (somatic mutation group 2 phenocluster) | GCST90624750 | 5.39e-04 |
| 9748 | CLEC14A/TNFRSF21 ratio | GCST90314082 | 5.39e-04 |
| 9749 | HEXIM1/IKBKG ratio | GCST90315045 | 5.37e-04 |
| 9750 | eosinophil (absolute count, mean, inv-norm transformed) | GCST90475291 | 5.37e-04 |
| 9751 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T489 | ECGU000489 | 5.35e-04 |
| 9752 | RETN/RNASET2 ratio | GCST90315768 | 5.35e-04 |
| 9753 | STMN3 levels | GCST90242894 | 5.35e-04 |
| 9754 | Alzheimer's disease (MTAG) | GCST90449055 | 5.35e-04 |
| 9755 | CD69/EDAR ratio | GCST90313875 | 5.34e-04 |
| 9756 | Other diseases of the digestive system | FING00001010 | 5.34e-04 |
| 9757 | GIPC3 levels | GCST90469348 | 5.33e-04 |
| 9758 | Waist-hip index | GCST012228 | 5.32e-04 |
| 9759 | Polyunsaturated fatty acids to total fatty acids percentage | GCST90502645 | 5.31e-04 |
| 9760 | ICAM4 levels | GCST90469501 | 5.31e-04 |
| 9761 | IDP dMRI ProbtrackX ICVF cgh r | GCST90004382 | 5.31e-04 |
| 9762 | LTA/LTBR ratio | GCST90315336 | 5.30e-04 |
| 9763 | IL2RA/NCR1 ratio | GCST90315161 | 5.30e-04 |
| 9764 | Polyunsaturated fatty acids to total fatty acids percentage | GCST90502649 | 5.29e-04 |
| 9765 | mean corpuscular hemoglobin (MCH, mean, inv-norm transformed) | GCST90475446 | 5.29e-04 |
| 9766 | Polyunsaturated fatty acids to saturated fatty acids ratio | GCST90502597 | 5.28e-04 |
| 9767 | Plasma 3-hydroxybutyroylglycine** levels in chronic kidney disease | GCST90264488 | 5.28e-04 |
| 9768 | FBP1/GSTA1 ratio | GCST90314786 | 5.28e-04 |
| 9769 | Volume of right accessory basal nucleus | GCST90475009 | 5.27e-04 |
| 9770 | Glomerular filtration rate in non diabetics (creatinine) | GCST003401 | 5.27e-04 |
| 9771 | Alzheimer's disease (MTAG) | GCST90449062 | 5.27e-04 |
| 9772 | GPLD1 levels | GCST90086890 | 5.25e-04 |
| 9773 | TNFSF12 levels | GCST90274846 | 5.20e-04 |
| 9774 | Aspartate aminotransferase (AST, mean, inv-norm transformed) | GCST90475121 | 5.17e-04 |
| 9775 | Waist-to-hip ratio adjusted for BMI | GCST90025996 | 5.17e-04 |
| 9776 | T1 FreeSurfer DK lh lateraloccipital area | GCST90385598 | 5.17e-04 |
| 9777 | ADH4/RBP5 ratio | GCST90313194 | 5.12e-04 |
| 9778 | INPP1/NT5C3A ratio | GCST90315177 | 5.12e-04 |
| 9779 | Hyperthyroidism | GCST90468136 | 5.11e-04 |
| 9780 | ANG levels | GCST90468307 | 5.11e-04 |
| 9781 | PECAM1 levels | GCST90470206 | 5.11e-04 |
| 9782 | BAIAP2 levels | GCST90468419 | 5.11e-04 |
| 9783 | Certain disorders involving the immune mechanism | FING00000264 | 5.09e-04 |
| 9784 | SERPINA4 levels | GCST90470584 | 5.09e-04 |
| 9785 | Right-hemisphere somatomotor network to pallidum white-matter structural connectivity | GCST90302797 | 5.08e-04 |
| 9786 | Lipoma of skin and subcutaneous tissue (PheCode 214.1) | GCST90475619 | 5.08e-04 |
| 9787 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T494 | ECGU000494 | 5.07e-04 |
| 9788 | IDP T1 FIRST left hippocampus volume | GCST90002444 | 5.06e-04 |
| 9789 | T1 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 47) | GCST90320610 | 5.06e-04 |
| 9790 | MANF/SDC4 ratio | GCST90315367 | 5.06e-04 |
| 9791 | CD276 levels | GCST90468614 | 5.05e-04 |
| 9792 | ANGPT1/DKK1 ratio | GCST90313263 | 5.04e-04 |
| 9793 | NBL1/TGFBR2 ratio | GCST90315515 | 5.04e-04 |
| 9794 | Lung adenocarcinoma | GCST004744 | 5.02e-04 |
| 9795 | Hyperglyceridemia (PheCode 272.12) | GCST90475724 | 5.02e-04 |
| 9796 | Umbilical hernia (PheCode 550.4) | GCST90476062 | 5.01e-04 |
| 9797 | INPPL1 levels | GCST90469619 | 5.01e-04 |
| 9798 | FHIT/PRTFDC1 ratio | GCST90314823 | 5.00e-04 |
| 9799 | C1QTNF5 levels | GCST90468489 | 4.98e-04 |
| 9800 | DGKA levels | GCST90468989 | 4.97e-04 |
| 9801 | Hypothyroidism NOS | endocrine/metabolic | UKBB00000336 | 4.97e-04 |
| 9802 | GP6/SEMA4D ratio | GCST90314971 | 4.96e-04 |
| 9803 | FLT4 levels | GCST90469252 | 4.96e-04 |
| 9804 | eGFR in diabetes mellitus (loose) kidney healthy controls (full adjustment) | GCST90624793 | 4.95e-04 |
| 9805 | NFATC1/SPRY2 ratio | GCST90315539 | 4.95e-04 |
| 9806 | F9/PROC ratio | GCST90314748 | 4.95e-04 |
| 9807 | CD70 levels | GCST90468645 | 4.95e-04 |
| 9808 | Linoleic acid levels | GCST90502311 | 4.94e-04 |
| 9809 | Hernia abdominopelvic cavity | GCST90086087 | 4.93e-04 |
| 9810 | Bone marrow fat fraction of left proximal femur | GCST90652392 | 4.93e-04 |
| 9811 | Triacylglycerol_56:5_[M+NH4]1+ levels | GCST90060554 | 4.92e-04 |
| 9812 | Omega-6 fatty acids to total fatty acids percentage | GCST90499210 | 4.91e-04 |
| 9813 | THBS4 levels | GCST90470855 | 4.90e-04 |
| 9814 | SELP/VSIR ratio | GCST90315822 | 4.89e-04 |
| 9815 | 5alpha-androstan-3alpha,17beta-diol monosulfate (1) levels | GCST90199858 | 4.89e-04 |
| 9816 | PLAU levels | GCST90470252 | 4.88e-04 |
| 9817 | TPP1 levels | GCST90470946 | 4.87e-04 |
| 9818 | T1 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 46) | GCST90320609 | 4.87e-04 |
| 9819 | Eczema | GCST90468126 | 4.87e-04 |
| 9820 | Alanine transaminase (ALT, minimum, inv-norm transformed) | GCST90475115 | 4.87e-04 |
| 9821 | B4GALT1/SMOC2 ratio | GCST90313433 | 4.87e-04 |
| 9822 | TNFRSF11A levels | GCST90470902 | 4.86e-04 |
| 9823 | CPXM1/HBEGF ratio | GCST90314219 | 4.85e-04 |
| 9824 | Epstein-Barr virus EA-D antibody levels | GCST90006898 | 4.84e-04 |
| 9825 | LAMP1 levels | GCST90469733 | 4.81e-04 |
| 9826 | Phospholipids in IDL | GCST90497628 | 4.81e-04 |
| 9827 | DTI TBSS MD Cingulum cingulate gyrus R | GCST90384606 | 4.79e-04 |
| 9828 | Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T60 | ECGA000060 | 4.79e-04 |
| 9829 | PAK4 levels | GCST90470150 | 4.79e-04 |
| 9830 | CRKL/DBNL ratio | GCST90314263 | 4.75e-04 |
| 9831 | Free thyroxine levels within normal range in pregnancy | GCST90435196 | 4.75e-04 |
| 9832 | triglyceride (maximum, inv-norm transformed) | GCST90476429 | 4.75e-04 |
| 9833 | ATP5IF1/F2R ratio | GCST90313384 | 4.75e-04 |
| 9834 | Tyrosine levels | GCST90243425 | 4.75e-04 |
| 9835 | Monounsaturated fatty acids to total fatty acids percentage | GCST90502049 | 4.74e-04 |
| 9836 | Sphingomyelin_34:2_[M+H]1+ levels | GCST90060235 | 4.73e-04 |
| 9837 | Triglycerides to Total Lipids in Very Large HDL percentage | GCST90500506 | 4.73e-04 |
| 9838 | Psoriasis vulgaris | FING00001224 | 4.72e-04 |
| 9839 | DLK1 levels | GCST90469003 | 4.70e-04 |
| 9840 | CXCL11 levels | GCST90468924 | 4.70e-04 |
| 9841 | Diastolic blood pressure | GCST90025981 | 4.69e-04 |
| 9842 | ITGB1BP2/TIA1 ratio | GCST90315222 | 4.69e-04 |
| 9843 | EDAR/IPCEF1 ratio | GCST90314578 | 4.68e-04 |
| 9844 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T107 | ECGU000107 | 4.67e-04 |
| 9845 | CTSZ/NAAA ratio | GCST90314320 | 4.67e-04 |
| 9846 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T118 | ECGU000118 | 4.65e-04 |
| 9847 | ABL1 levels | GCST90468190 | 4.63e-04 |
| 9848 | Cholesteryl Esters to Total Lipids in IDL percentage | GCST90497549 | 4.63e-04 |
| 9849 | EPCAM/GPA33 ratio | GCST90314674 | 4.62e-04 |
| 9850 | Total lipids in large VLDL | GCST90498216 | 4.59e-04 |
| 9851 | Asthma (childhood onset) | GCST007800 | 4.59e-04 |
| 9852 | DAG1/DBNL ratio | GCST90314372 | 4.58e-04 |
| 9853 | SYTL4 levels | GCST90470795 | 4.58e-04 |
| 9854 | IDP dMRI TBSS L2 Cingulum hippocampus L | GCST90004160 | 4.58e-04 |
| 9855 | BST2/CXADR ratio | GCST90313538 | 4.56e-04 |
| 9856 | IGF2R/LGMN ratio | GCST90315131 | 4.56e-04 |
| 9857 | GIT1 levels | GCST90469351 | 4.55e-04 |
| 9858 | CD20 on IgD- CD27- B cell | GCST90001754 | 4.55e-04 |
| 9859 | lymphocyte (absolute count, mean, inv-norm transformed) | GCST90475426 | 4.55e-04 |
| 9860 | Nonspecific elevation of levels of transaminase or lactic acid dehydrogenase [LDH] (PheCode 573.6) | GCST90476094 | 4.55e-04 |
| 9861 | CCN4 levels | GCST90468590 | 4.55e-04 |
| 9862 | Phosphatidylcholine_34:2_[M+H]1+/Phosphatidylethanolamine_37:2_[M+H]1+/Phosphatidate_39:3_[M+NH4]1+ levels | GCST90060303 | 4.55e-04 |
| 9863 | SCAMP3 levels | GCST90470532 | 4.54e-04 |
| 9864 | Alkenylphosphatidylethanolamine (P-20:0/18:2) levels | GCST90025056 | 4.53e-04 |
| 9865 | Subclinical hyperthyroidism in pregnancy | GCST90435199 | 4.52e-04 |
| 9866 | CA5A/KRT18 ratio | GCST90313592 | 4.52e-04 |
| 9867 | ICA1 levels | GCST90469497 | 4.52e-04 |
| 9868 | CD38/RELT ratio | GCST90313809 | 4.51e-04 |
| 9869 | Phospholipids to total lipids in small LDL percentage (UKB data field 23624) | GCST90269721 | 4.50e-04 |
| 9870 | PSMD9/UBAC1 ratio | GCST90315735 | 4.50e-04 |
| 9871 | CD69/F2R ratio | GCST90313877 | 4.50e-04 |
| 9872 | Total fatty acid levels | GCST90502726 | 4.49e-04 |
| 9873 | SCAMP3/STX4 ratio | GCST90315805 | 4.49e-04 |
| 9874 | T1 FreeSurfer aseg Right-choroid-plexus | GCST90384170 | 4.47e-04 |
| 9875 | DNAJB14 levels | GCST90469011 | 4.47e-04 |
| 9876 | Treatment/medication code - salbutamol | Medications | UKBB00000857 | 4.44e-04 |
| 9877 | Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T111 | ECGA000111 | 4.44e-04 |
| 9878 | PTPN6 levels | GCST90470377 | 4.43e-04 |
| 9879 | Polyunsaturated fatty acids to monounsaturated fatty acids ratio | GCST90502567 | 4.43e-04 |
| 9880 | DTI autoptx MD fma tract | GCST90385230 | 4.43e-04 |
| 9881 | Phospholipids to Total Lipids in Large VLDL percentage | GCST90498252 | 4.43e-04 |
| 9882 | PRTN3 levels | GCST90470348 | 4.42e-04 |
| 9883 | PTPRF/PTPRS ratio | GCST90315751 | 4.42e-04 |
| 9884 | Edema (PheCode 782.3) | GCST90476272 | 4.41e-04 |
| 9885 | CCN2/ENO2 ratio | GCST90313712 | 4.39e-04 |
| 9886 | CDKN2D/FOXO1 ratio | GCST90313985 | 4.38e-04 |
| 9887 | Triacylglycerol_54:3_[M+NH4]1+ levels | GCST90060541 | 4.37e-04 |
| 9888 | Mean corpuscular hemoglobin | GCST004630 | 4.36e-04 |
| 9889 | Spinal stenosis of lumbar region (PheCode 720.1) | GCST90476234 | 4.36e-04 |
| 9890 | Triacylglycerol_50:2_[M+NH4]1+ levels | GCST90060473 | 4.35e-04 |
| 9891 | RUNX3 levels | GCST90242706 | 4.35e-04 |
| 9892 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T25 | ECGU000025 | 4.34e-04 |
| 9893 | Octadecanedioylcarnitine (C18-DC) levels | GCST90199992 | 4.34e-04 |
| 9894 | LAT2 levels | GCST90469739 | 4.33e-04 |
| 9895 | Concentration of LDL particles | GCST90498413 | 4.33e-04 |
| 9896 | Alanine transaminase (ALT, mean, inv-norm transformed) | GCST90475112 | 4.32e-04 |
| 9897 | RP2 levels | GCST90470493 | 4.32e-04 |
| 9898 | CD200R1/CLEC4G ratio | GCST90313748 | 4.31e-04 |
| 9899 | ADGRE2/B4GALT1 ratio | GCST90313174 | 4.31e-04 |
| 9900 | TNFRSF9 levels | GCST90470916 | 4.31e-04 |
| 9901 | Platelet distribution width | GCST004616 | 4.29e-04 |
| 9902 | APOA1 levels | GCST90497122 | 4.29e-04 |
| 9903 | HMOX1 levels | GCST90469465 | 4.29e-04 |
| 9904 | BANK1/FOXO1 ratio | GCST90313456 | 4.29e-04 |
| 9905 | ANGPTL3 levels | GCST90468304 | 4.29e-04 |
| 9906 | BCAN/DPP6 ratio | GCST90313478 | 4.29e-04 |
| 9907 | Volume of right cortical nucleus | GCST90474919 | 4.28e-04 |
| 9908 | FIS1 levels | GCST90469240 | 4.28e-04 |
| 9909 | GOT1 levels | GCST90469379 | 4.26e-04 |
| 9910 | CSF1/IFNGR1 ratio | GCST90314283 | 4.24e-04 |
| 9911 | CXADR levels | GCST90468922 | 4.24e-04 |
| 9912 | Omega-6 fatty acids to total fatty acids percentage | GCST90502541 | 4.23e-04 |
| 9913 | NECTIN2/VSIR ratio | GCST90315533 | 4.23e-04 |
| 9914 | TCN1 levels | GCST90470819 | 4.23e-04 |
| 9915 | COL1A1/OMD ratio | GCST90314171 | 4.23e-04 |
| 9916 | MTDH levels | GCST90469954 | 4.22e-04 |
| 9917 | APBB1IP/NADK ratio | GCST90313298 | 4.22e-04 |
| 9918 | CD163/MSR1 ratio | GCST90313738 | 4.22e-04 |
| 9919 | FAP/THBS4 ratio | GCST90314785 | 4.21e-04 |
| 9920 | EGLN1/LSP1 ratio | GCST90314617 | 4.20e-04 |
| 9921 | TWF2 levels | GCST90470987 | 4.19e-04 |
| 9922 | HBEGF/LAT2 ratio | GCST90315032 | 4.18e-04 |
| 9923 | GALNT3 levels | GCST90469297 | 4.17e-04 |
| 9924 | EDAR/TXNDC5 ratio | GCST90314593 | 4.16e-04 |
| 9925 | Frozen shoulder | GCST90000513 | 4.16e-04 |
| 9926 | FADD/NFATC1 ratio | GCST90314771 | 4.15e-04 |
| 9927 | CCL19 levels | GCST90468571 | 4.15e-04 |
| 9928 | CD244/CD84 ratio | GCST90313762 | 4.15e-04 |
| 9929 | WFIKKN1 levels | GCST90471076 | 4.14e-04 |
| 9930 | CD300LF levels | GCST90468622 | 4.13e-04 |
| 9931 | Triacylglycerol_52:3_[M+NH4]1+ levels | GCST90060509 | 4.13e-04 |
| 9932 | HippSubfield lh volume Whole-hippocampal-head | GCST90002688 | 4.13e-04 |
| 9933 | mean corpuscular hemoglobin (MCH, maximum, inv-norm transformed) | GCST90475442 | 4.12e-04 |
| 9934 | Omega-6 fatty acids to total fatty acids percentage | GCST90502129 | 4.12e-04 |
| 9935 | Rheumatoid arthritis | GCST000679 | 4.12e-04 |
| 9936 | BCAM/LGALS4 ratio | GCST90313473 | 4.12e-04 |
| 9937 | KIF22 levels | GCST90469682 | 4.11e-04 |
| 9938 | AXIN1/CLIP2 ratio | GCST90313404 | 4.10e-04 |
| 9939 | T2 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 106) | GCST90320925 | 4.10e-04 |
| 9940 | Idiopathic gout | FING00000658 | 4.09e-04 |
| 9941 | Free Cholesterol to Total Lipids in Large VLDL percentage | GCST90498204 | 4.08e-04 |
| 9942 | LYPD3 levels | GCST90469828 | 4.07e-04 |
| 9943 | Omega-3 fatty acids to total fatty acids percentage | GCST90502081 | 4.07e-04 |
| 9944 | GORASP2 levels | GCST90469378 | 4.07e-04 |
| 9945 | COL6A3/SMOC2 ratio | GCST90314178 | 4.06e-04 |
| 9946 | lymphocyte (absolute count, minimum, inv-norm transformed) | GCST90475429 | 4.06e-04 |
| 9947 | SCGN levels | GCST90470544 | 4.06e-04 |
| 9948 | Operative procedures - Haemorrhoidectomy | Summary Operations | UKBB00000580 | 4.05e-04 |
| 9949 | FCRL2 levels | GCST90469206 | 4.04e-04 |
| 9950 | SLPI levels | GCST90426030 | 4.04e-04 |
| 9951 | CST6/GAL ratio | GCST90314302 | 4.03e-04 |
| 9952 | STIP1/TMSB10 ratio | GCST90315890 | 4.03e-04 |
| 9953 | DNAJA2 levels | GCST90469009 | 4.03e-04 |
| 9954 | Triacylglycerol_56:4_[M+NH4]1+ levels | GCST90060556 | 4.03e-04 |
| 9955 | CD74 levels | GCST90468647 | 4.02e-04 |
| 9956 | JAM3 levels | GCST90469660 | 4.02e-04 |
| 9957 | PPP1R12A/VEGFC ratio | GCST90315715 | 4.02e-04 |
| 9958 | ITGAM levels | GCST90469638 | 4.02e-04 |
| 9959 | INSL5 levels | GCST90469622 | 4.02e-04 |
| 9960 | DCBLD2 levels | GCST90468952 | 4.02e-04 |
| 9961 | CRKL/FIS1 ratio | GCST90314266 | 4.01e-04 |
| 9962 | Cholesterol to Total Lipids in Medium VLDL percentage | GCST90498919 | 4.00e-04 |
| 9963 | Other diseases of liver | FING00001004 | 4.00e-04 |
| 9964 | Eosinophil percentage of white cells | GCST004600 | 4.00e-04 |
| 9965 | AXIN1/HEXIM1 ratio | GCST90313408 | 4.00e-04 |
| 9966 | NDUFB7 levels | GCST90470015 | 3.99e-04 |
| 9967 | Telomere length (principal component 2) | GCST90435145 | 3.98e-04 |
| 9968 | CELA3A/CTRB1 ratio | GCST90314011 | 3.97e-04 |
| 9969 | SOST levels | GCST90470711 | 3.96e-04 |
| 9970 | Type 1 diabetes with neurological manifestations (PheCode 250.14) | GCST90475664 | 3.96e-04 |
| 9971 | DPY30 levels | GCST90469037 | 3.95e-04 |
| 9972 | Blood cell traits latent factor 3 (white cell) | GCST90559245 | 3.95e-04 |
| 9973 | 1-(1-enyl-palmitoyl)-2-palmitoleoyl-GPC (P-16:0/16:1) levels | GCST90200070 | 3.95e-04 |
| 9974 | Cholesterol to Total Lipids in Large VLDL percentage | GCST90498125 | 3.94e-04 |
| 9975 | FYB1/PDGFB ratio | GCST90314912 | 3.94e-04 |
| 9976 | Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T103 | ECGA000103 | 3.94e-04 |
| 9977 | LTBR levels | GCST90469816 | 3.94e-04 |
| 9978 | 21-hydroxypregnenolone disulfate levels | GCST90199849 | 3.94e-04 |
| 9979 | Total free cholesterol levels | GCST90500063 | 3.93e-04 |
| 9980 | Concentration of small HDL particles | GCST90499461 | 3.93e-04 |
| 9981 | DTI autoptx L2 ifo r tract | GCST90385179 | 3.93e-04 |
| 9982 | Acute laryngitis and tracheitis | FING00000023 | 3.93e-04 |
| 9983 | ICAM5 levels | GCST90469502 | 3.91e-04 |
| 9984 | T1 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 66) | GCST90320629 | 3.91e-04 |
| 9985 | CCL5/LAMA4 ratio | GCST90313703 | 3.90e-04 |
| 9986 | ERP44 levels | GCST90469150 | 3.90e-04 |
| 9987 | Cholesterol in small HDL (UKB data field 23575) | GCST90269672 | 3.90e-04 |
| 9988 | Monounsaturated fatty acids to total fatty acids percentage | GCST90502385 | 3.89e-04 |
| 9989 | OGA levels | GCST90470117 | 3.89e-04 |
| 9990 | Polyunsaturated fatty acids to monounsaturated fatty acids ratio | GCST90502153 | 3.88e-04 |
| 9991 | Non-albumin protein levels | UKBB00000503 | 3.88e-04 |
| 9992 | Concentration of small HDL particles (UKB data field 23572) | GCST90269669 | 3.88e-04 |
| 9993 | IDP T1 FIRST right pallidum volume | GCST90002443 | 3.88e-04 |
| 9994 | TMSB10/TXNRD1 ratio | GCST90315925 | 3.88e-04 |
| 9995 | SH3GLB2 levels | GCST90470621 | 3.87e-04 |
| 9996 | Neutrophil percentage of granulocytes | GCST004623 | 3.86e-04 |
| 9997 | ITGA5 levels | GCST90469635 | 3.84e-04 |
| 9998 | WWP2 levels | GCST90471080 | 3.84e-04 |
| 9999 | Snoring | GCST009763 | 3.84e-04 |
| 10000 | CNTN2 levels | GCST90468804 | 3.81e-04 |